Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2016 | Phase 1b trial of CRS-207 with chemotherapy for malignant pleural mesothelioma

David Carbone • 15 Apr 2016
ELCC 2016
Lung Cancer

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, discusses a phase 1b trial of the anti-mesothelin vaccine CRS-207 plus chemotherapy as frontline treatment for malignant pleural mesothelioma.

More from David Carbone

1:13
Early detection and interception in lung cancer
David Carbone • 17 Apr 2023
0:32
Can addition of novel ICIs improve PD-(L)1 blockade in NSCLC?
David Carbone • 17 Apr 2023
1:52
Is adjuvant immunotherapy necessary in non-small cell lung cancer?
David Carbone • 17 Apr 2023
1:39
LCMC3: adjuvant and neoadjuvant atezolizumab in early-stage NCSLC
David Carbone • 17 Apr 2023

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals